Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Efficacy and safety of anti-hyperglycaemic drugs in patients with non-alcoholic fatty liver disease with or without diabetes: An updated systematic review of randomized controlled trials
Alessandro Mantovani, Christopher D. Byrne, Eleonora Scorletti, et al.
Diabetes & Metabolism (2020) Vol. 46, Iss. 6, pp. 427-441
Open Access | Times Cited: 110

Showing 1-25 of 110 citing articles:

Management of Hyperglycemia in Type 2 Diabetes, 2022. A Consensus Report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)
Melanie J. Davies, Vanita R. Aroda, Billy S. Collins, et al.
Diabetes Care (2022) Vol. 45, Iss. 11, pp. 2753-2786
Open Access | Times Cited: 1158
Management of hyperglycaemia in type 2 diabetes, 2022. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)
Melanie J. Davies, Vanita R. Aroda, Billy S. Collins, et al.
Diabetologia (2022) Vol. 65, Iss. 12, pp. 1925-1966
Open Access | Times Cited: 680
The complex link between NAFLD and type 2 diabetes mellitus — mechanisms and treatments
Giovanni Targher, Kathleen E. Corey, Christopher D. Byrne, et al.
Nature Reviews Gastroenterology & Hepatology (2021) Vol. 18, Iss. 9, pp. 599-612
Closed Access | Times Cited: 586
NAFLD and increased risk of cardiovascular disease: clinical associations, pathophysiological mechanisms and pharmacological implications
Giovanni Targher, Christopher D. Byrne, Herbert Tilg
Gut (2020) Vol. 69, Iss. 9, pp. 1691-1705
Open Access | Times Cited: 581
NAFLD as a continuum: from obesity to metabolic syndrome and diabetes
Amélio F. Godoy‐Matos, Wellington S. Silva Júnior, Cynthia Melissa Valério
Diabetology & Metabolic Syndrome (2020) Vol. 12, Iss. 1
Open Access | Times Cited: 483
Glucagon-Like Peptide-1 Receptor Agonists for Treatment of Nonalcoholic Fatty Liver Disease and Nonalcoholic Steatohepatitis: An Updated Meta-Analysis of Randomized Controlled Trials
Alessandro Mantovani, Graziana Petracca, Giorgia Beatrice, et al.
Metabolites (2021) Vol. 11, Iss. 2, pp. 73-73
Open Access | Times Cited: 217
Non-alcoholic fatty liver disease, insulin resistance, metabolic syndrome and their association with vascular risk
Emir Muzurović, Dimitri P. Mikhailidis, Christos S. Mantzoros
Metabolism (2021) Vol. 119, pp. 154770-154770
Closed Access | Times Cited: 200
Efficacy of peroxisome proliferator-activated receptor agonists, glucagon-like peptide-1 receptor agonists, or sodium-glucose cotransporter-2 inhibitors for treatment of non-alcoholic fatty liver disease: a systematic review
Alessandro Mantovani, Christopher D. Byrne, Giovanni Targher
˜The œLancet. Gastroenterology & hepatology (2022) Vol. 7, Iss. 4, pp. 367-378
Open Access | Times Cited: 171
Treatments for NAFLD: State of Art
Alessandro Mantovani, Andrea Dalbeni
International Journal of Molecular Sciences (2021) Vol. 22, Iss. 5, pp. 2350-2350
Open Access | Times Cited: 164
The Relationship Between Type 2 Diabetes, NAFLD, and Cardiovascular Risk
Cyrielle Caussy, Adrien Aubin, Rohit Loomba
Current Diabetes Reports (2021) Vol. 21, Iss. 5
Open Access | Times Cited: 157
Nonalcoholic fatty liver disease as a metabolic disease in humans: A literature review
Bertrand Cariou, Christopher D. Byrne, Rohit Loomba, et al.
Diabetes Obesity and Metabolism (2021) Vol. 23, Iss. 5, pp. 1069-1083
Open Access | Times Cited: 143
Therapeutic targets, novel drugs, and delivery systems for diabetes associated NAFLD and liver fibrosis
Virender Kumar, Xiaofei Xin, Jingyi Ma, et al.
Advanced Drug Delivery Reviews (2021) Vol. 176, pp. 113888-113888
Open Access | Times Cited: 109
ISPAD Clinical Practice Consensus Guidelines 2022: Type 2 diabetes in children and adolescents
Amy S. Shah, Philip Zeitler, Jencia Wong, et al.
Pediatric Diabetes (2022) Vol. 23, Iss. 7, pp. 872-902
Open Access | Times Cited: 108
Risk of Heart Failure in Patients With Nonalcoholic Fatty Liver Disease
Alessandro Mantovani, Christopher D. Byrne, Giovanni Benfari, et al.
Journal of the American College of Cardiology (2022) Vol. 79, Iss. 2, pp. 180-191
Open Access | Times Cited: 83
Non-alcoholic fatty liver disease: pathophysiological concepts and treatment options
Christoph Grander, Felix Grabherr, Herbert Tilg
Cardiovascular Research (2023) Vol. 119, Iss. 9, pp. 1787-1798
Open Access | Times Cited: 79
NASH drug treatment development: challenges and lessons
Herbert Tilg, Christopher D. Byrne, Giovanni Targher
˜The œLancet. Gastroenterology & hepatology (2023) Vol. 8, Iss. 10, pp. 943-954
Open Access | Times Cited: 49
Gut microbiota modulation in patients with non-alcoholic fatty liver disease: Effects of current treatments and future strategies
Marta Maestri, Francesco Santopaolo, Maurizio Pompili, et al.
Frontiers in Nutrition (2023) Vol. 10
Open Access | Times Cited: 47
Epidemiology, screening, and co-management of type 2 diabetes mellitus and metabolic dysfunction–associated steatotic liver disease
Xiaolong Qi, Jie Li, Cyrielle Caussy, et al.
Hepatology (2024)
Open Access | Times Cited: 19
NAFLD, and cardiovascular and cardiac diseases: Factors influencing risk, prediction and treatment
Giovanni Targher, Kathleen E. Corey, Christopher D. Byrne
Diabetes & Metabolism (2020) Vol. 47, Iss. 2, pp. 101215-101215
Open Access | Times Cited: 132
Peroxisome Proliferator-Activated Receptors and Their Novel Ligands as Candidates for the Treatment of Non-Alcoholic Fatty Liver Disease
Anne Fougerat, Alexandra Montagner, Nicolas Loiseau, et al.
Cells (2020) Vol. 9, Iss. 7, pp. 1638-1638
Open Access | Times Cited: 114
Sodium-Glucose Cotransporter-2 Inhibitors for Treatment of Nonalcoholic Fatty Liver Disease: A Meta-Analysis of Randomized Controlled Trials
Alessandro Mantovani, Graziana Petracca, Alessandro Csermely, et al.
Metabolites (2020) Vol. 11, Iss. 1, pp. 22-22
Open Access | Times Cited: 103
Non‐alcoholic fatty liver disease‐related risk of cardiovascular disease and other cardiac complications
Christopher D. Byrne, Giovanni Targher
Diabetes Obesity and Metabolism (2021) Vol. 24, Iss. S2, pp. 28-43
Open Access | Times Cited: 79
Insights into Nonalcoholic Fatty-Liver Disease Heterogeneity
Marco Arrese, Juan Pablo Arab, Francisco Barrera, et al.
Seminars in Liver Disease (2021) Vol. 41, Iss. 04, pp. 421-434
Open Access | Times Cited: 78
Liraglutide Alleviates Hepatic Steatosis by Activating the TFEB-Regulated Autophagy-Lysosomal Pathway
Yunyun Fang, Linlin Ji, Chaoyu Zhu, et al.
Frontiers in Cell and Developmental Biology (2020) Vol. 8
Open Access | Times Cited: 76
Perspectives on Precision Medicine Approaches to NAFLD Diagnosis and Management
Amedeo Lonardo, Juan Pablo Arab, Marco Arrese
Advances in Therapy (2021) Vol. 38, Iss. 5, pp. 2130-2158
Open Access | Times Cited: 67
Page 1 - Next Page

Scroll to top